Sentinel Lymph Node Biopsy in Breast Cancer with <sup>99m</sup>Tc-Tilmanocept: A Multicenter Study on Real-Life Use of a Novel Tracer
Sergi Vidal‐Sicart, María Eugenia Rioja, Andrea Prieto, E. Goñi, Isabel Peligros Gómez, María Dolores Albala, Luis Lumbreras, Luisa Fernanda León, José Ramón Gómez, Francisco Campos
Abstract
<sup>99m</sup>Tc-tilmanocept is a novel radiopharmaceutical for sentinel lymph node (SLN) biopsy in breast cancer. Our aim was to describe results with <sup>99m</sup>Tc-tilmanocept in a heterogeneous group of breast cancer patients scheduled for SLN biopsy. <b>Methods:</b> Radiotracer preparation followed the manufacturer’s indications. Local protocols for SLN detection within 9 participant centers were not changed for the entire duration of the study. In total, 344 patients with T1–T4, N0–N2 breast cancer (352 lesions) were included. Superficial (intradermal or periareolar) or deep (peritumoral or intratumoral) injections were performed. The doses were adjusted depending on the scheduled time for surgery. <b>Results:</b> Lymphoscintigraphy was able to depict at least 1 SLN in 339 of 352 breast lesions (96.3%), and the intraoperative SLN detection rate reached 97.2%. On univariable analysis, SLN detection rates did not differ by age, clinical T or N stage, tumor location, histologic subtype, or prior neoadjuvant therapy. Lymphoscintigraphy showed higher SLN detection in patients with a normal weight (body mass index < 25) than in those who were overweight or obese (body mass index ≥ 25), at 99.2% versus 94.6%, respectively (<i>P</i> = 0.031). The proportion of patients with preoperative lymphoscintigraphic detection or excised SLNs was higher with superficial than deep injections. Reinjected cases were significantly lower when superficial injection was chosen first (<i>P</i> < 0.001). Injection site and the tumor markers human epidermal growth factor receptor 2 and estrogen receptor had an impact on preoperative SLN visualization and intraoperative localization. In 80 cases, SLN biopsy resulted in a positive lymph node. During a mean follow-up of 19 mo, no axillary recurrences were observed. <b>Conclusion:</b> Whatever the protocol, <sup>99m</sup>Tc-tilmanocept showed good results in a heterogeneous breast cancer population, although the best results were achieved when a superficial injection was chosen.